Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Diffuse hair thinning and treatments like finasteride and minoxidil. Early detection and treatment are crucial for effective management.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

The conversation discusses coping with hair loss, with the original poster using finasteride and derma rolling as treatments. They express insecurity about their appearance, choosing to grow their hair long to hide balding, while others suggest different hairstyles and self-care strategies.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.

Aspirin reduces the effectiveness of minoxidil for hair loss. Quercetin and 5-ASA medications also inhibit the necessary enzyme for minoxidil to work.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

Regret over not starting hair loss treatments like finasteride and minoxidil earlier, leading to significant hair loss. Users discuss coping strategies, including buzzing hair, staying on medications, and considering future treatments.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.

Many users report not experiencing a shedding phase while using finasteride, with some also using minoxidil or dutasteride without shedding. Some believe shedding might be mistaken for normal hair loss, while others note micro sheds or no shedding at all.

Mixing dutasteride capsules and tretinoin cream into liquid minoxidil is questioned for effectiveness. A user responds negatively.

Stopping Minoxidil leads to hair reverting to its natural state, while stopping Finasteride may delay but not prevent eventual hair loss progression. Finasteride slows hair loss by reducing DHT damage, but once stopped, hair loss resumes, potentially at a slower rate.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

A user discusses their positive experience with finasteride, criticizing others for spreading fear about side effects. They emphasize that side effects are often temporary and not as common as some suggest.

The user switched from finasteride to dutasteride after 30 months with no progress, experiencing a significant shed initially. The current treatment includes daily dutasteride, oral minoxidil, topical finasteride and minoxidil, derma stamping, PRP, and calecim exosomes.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The user has been using minoxidil and finasteride without success and is now trying a new product called Arata Mitoactive, which contains the ingredient y100. They plan to review its effectiveness themselves due to a lack of existing reviews.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.